Sue Desmond-Hellmann is a physician, scientist and philanthropist, who has devoted her career to improving the human condition. As a pioneer in healthcare for more than 30 years, she’s driven major developments toward the eradication of disease, poverty and inequity. She credits a move to Uganda in 1989 - to work on HIV/AIDS and cancer alongside her husband, Nick - as a turning point. “It was so profound to recognize…that all the learning I had done to become a doctor didn’t matter at all if I didn’t make a contribution,” she says. Today, as CEO of the Bill & Melinda Gates Foundation, Dr. Desmond-Hellmann leads the organization’s vision for a world where every person has the opportunity to live a healthy, productive life. Drawing on her diverse experience in both the public and private sectors, she creates an environment for talented and committed individuals to help more children and young people survive and thrive, combat infectious diseases that hit the poorest hardest, and empower people - particularly women and girls - to transform their lives.
Dr. Penny Heaton is the Chief Executive Officer of the recently announced Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit medical research institute that aims to accelerate translational science to combat diseases that disproportionately impact the poor in low- and middle-income countries. Dr. Heaton will lead the institute’s work to capitalize on new strategies that could increase the identification, selection, and optimization of novel candidates for drugs, vaccines, monoclonal antibodies, and diagnostics to eradicate malaria, accelerate the end of the TB epidemic and prevent diarrheal deaths from occurring in children.
The session, led by Peter Marks and Janet Woodcock, will be organized as an interactive, moderated roundtable discussion of FDA center priorities followed by a question-and-answer session with the audience. Topics that will be addressed during the roundtable will include the FDA’s perspectives on critical topics such as PDUFA VI implementation; efforts to advance innovation and expedite patient access to novel therapies for serious and life-threatening conditions; novel approaches to integrating new scientific tools into FDA regulatory practices at all levels; and FDA resources and scientific infrastructure.
The role of the patient has evolved dramatically over the past decade. Not only are patients increasingly more involved in their healthcare decision making, they are also passionate advocates who work tirelessly to advance drug development research and development and secure a public policy environment that is patient-centric. Join a discussion with patient advocates as they discuss their journeys to diagnosis and their viewpoints on our healthcare system. They will share their perspectives on what it means to be a patient and how they are advocating in their own unique ways to achieve a common goal: bringing new treatments to patients.
|Julie Gerberding, MD
Executive Vice President & Chief Patient Officer, Strategic Communications,
Global Public Policy and Population Health, Merck
Intel Health and Life Sciences Strategist, Patient and Precision Medicine Pioneer
|Dr. Jay Bradner
President at Novartis Institutes for Biomedical Research (NIBR)